CBD Candid

US CBD brands, reviewed with candor

News

Square Sets an October 15 Cut-Off for CBD Sellers

The payment processor has told merchants to strip CBD and hemp products from their catalogs a month before the federal rule lands. A processor's decision is not a legal one — but it hits the shelf first.

By Staff, CBD Candid 2 min read

The first date that changes what you can buy this fall is not a legal deadline. It is a payments one.

According to trade reporting dated August 7, Square has notified merchants that CBD and hemp-derived products must come off their catalogs by October 15, 2026, and that selling them “will no longer be permitted on Square’s platform” after that. The same report gives the company’s stated reason: the federal law taking effect on November 12 that redefines which hemp products are legal.

The gap between the two dates

October 15 sits roughly four weeks ahead of the statute it cites. That gap is the story.

A processor withdrawing from a category is a commercial decision, not a prohibition. Nothing about Square’s notice makes CBD illegal, and nothing in it is a ruling on any individual product. What it does do is remove the checkout button — and for a small brand whose entire storefront runs on Square, that arrives well before any rulebook does.

The notice also appears to sweep broadly. The federal change is aimed at total THC per container — the same Marijuana Moment report puts the new threshold at 0.4 milligrams per container, though we haven’t seen that number in the statutory text itself — yet a plain, non-intoxicating CBD isolate tincture sells through the same processor as everything else. Read as reported, the cut-off doesn’t sort by cannabinoid.

What to actually check

If you buy from a small independent brand, the practical exposure is narrow but real. Recurring subscriptions billed through a Square account may simply stop. Stored cards on a brand’s Square-hosted checkout are worth a look now rather than in mid-October. Larger sellers with their own merchant relationships are less likely to be affected at all.

None of this changes what these products are: the FDA has not evaluated them, they are not intended to diagnose, treat, cure or prevent any disease, and they are sold to adults only.

What we could not confirm

We couldn’t locate a public Square policy page stating this change; the company’s prohibited-goods URL returned an error when we checked. Every element above is attributed to trade reporting, and we will update if Square publishes its own notice.

The underlying date is still moving too — we covered the possible slip in the effective date earlier this month. Processors, it turns out, don’t wait for Congress to finish arguing.